BIMINI Biotech is a Leiden-based preclinical biotech company developing first-in-class small-molecule modulators of the Wiskott–Aldrich Syndrome protein (WASp) for hematological cancers and autoimmune diseases. The company focuses on targeting actin cytoskeleton signaling to develop novel therapies for diseases with high unmet medical need. BIMINI is at the preclinical stage and advancing a pipeline of proprietary WASp agonists and antagonists toward clinical development. Visite our website.
